✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Growth Hormone · Peptide Reference

CJC-1295 / Ipamorelin

Released: Last reviewed:

Combination of a GHRH analog (CJC-1295) and a selective ghrelin-receptor agonist (ipamorelin). Stimulates endogenous GH and IGF-1 release with minimal cortisol or prolactin elevation.

Growth Hormone Evidence grade: B Not FDA-approved
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Key facts

Class
GHRH analog + ghrelin-receptor agonist
CJC-1295 form
No DAC (no Drug Affinity Complex) — short half-life ~30 min
Ipamorelin half-life
~2 hours
Pharmacy pathway
See the dated FDA status notice above
Sports-ban status
WADA prohibited (S2 — Peptide Hormones)
Common dose
100-300 mcg of each, SC, 2-3x daily pre-meal or pre-bed
Evidence grade
B (small human pharmacokinetic studies)
FDA status
Not FDA-approved (compounded)

Mechanism of action

Combination of a GHRH analog (CJC-1295) and a selective ghrelin-receptor agonist (ipamorelin). Stimulates endogenous GH and IGF-1 release with minimal cortisol or prolactin elevation.

Standard dosing

Typical clinical use: 100-300 mcg of each, SC, 2-3x daily pre-meal or pre-bed. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. CJC-1295 / Ipamorelin requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved (compounded). FDA limits which peptides a pharmacy may compound; check this page’s dated FDA status notice before assuming a peptide is legally available. Ask which licensed pharmacy fills the prescription and check that pharmacy’s license with your state board of pharmacy.

U.S. telehealth providers prescribing CJC-1295 / Ipamorelin

The most commonly cited U.S. telehealth providers for CJC-1295 / Ipamorelin are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD —, whose offerings for this peptide we have not verified (see the FDA status notice above). See the full provider directory for complete profiles.

Trade-offs to know

CJC-1295 / Ipamorelin carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved, cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that names its pharmacy, explains its follow-up schedule and states the regulatory status of what it prescribes.

Related peptides in the growth hormone category

Editorial team

Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
  2. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28526632
  3. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.